Our findings demonstrated that GGCLT treatment improved liver fibrosis caused by BDL in mice, in part through a decrease in HIF-1α-induced elevation of inflammation, oxidative stress, and angiogenesis-related factors. This evidence concerns the gene HIF1A and Hepatic fibrosis.